1.40
1.40 (0%)
As of Feb 14, 2025
Synlogic, Inc. [SYBX]
Source:
Company Overview
Synlogic, Inc. is a biopharmaceutical company that advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU).
Country | United States |
Headquarters | cambridge, massachusetts |
Phone Number | 617-401-9975 |
Industry | manufacturing |
CEO | Aoife Brennan |
Website | www.synlogictx.com |